Regulatory approval

Published by the Health Service Executive. Approved

The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin for reimbursement as a treatment option for the treatment of adult patients with CD30+ Hodgkins Lymphoma (HL) at increased risk of relapse or progression following an autologous hematopoietic stem cell transplant (ASCT).

This is written in the approval document as:

Treatment of adult patients with CD30+ Hodgkins Lymphoma (HL) at increased risk of relapse or progression following an autologous haematopoietic stem cell transplant (ASCT).

Reimbursement

ODMS

Citation

Brentuximab vedotin Monotherapy, 2025, version number 6, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6333/234_v6_Brentuximab.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
HSE (1) CD30 + Hodgkin Lymphoma Brentuximab vedotin

Contributions

Date Contributor Description
2024-01-16 Van Allen lab Adding HSE approvals for reimbursement to database
2022-12-01 Health Service Executive Indication approved for reimbursement.